

Table. This table shows the results regarding neonatal hyperfibrinolysis and fibrinogen's insufficiency (Maximum Clot Firmness -MCF- in Fibrinogen Rotational Thromboelastometry -FIBTEM- < 9 mm) in relation to cytokines and Endothelin 1 (ET1).

NEONATES							
	Neonates born to PE <sup>1</sup> mothers (N=34)	Neonates born to healthy mothers (N=47)	P-Value				
Hyperfibrinolysis	10/34 (29.4%)	11/47 (23.4%)	0.54				
MCF <sup>2</sup>	19/34 (55.9%)	14/47 (29.8%)	<b>0.02</b>				
FIBTEM <sup>3</sup> < 13mm	9/34 (26.5%)	8/47 (17%)	0.30				
MCF INTEM <sup>4</sup> < 48mm	10/34 (29.4%)	4/47 (8.5%)	<b>0.01</b>				
MCF EXTEM <sup>5</sup> < 45mm							
	Neonates born to Non-Severe PE mothers (N=21)	Neonates born to Severe PE mothers (N=13)	Neonates born to healthy mothers (N=47)	P-Value	Non-Severe PE VS Severe PE	Non-Severe PE VS Controls	Severe PE VS Controls
Hyperfibrinolysis	6/21 (28.6%)	4/13 (30.8%)	11/47 (23.4%)	0.83**	-	-	-
MCF FIBTEM < 13mm	10/21 (47.6%)	9/13 (69.2%)	14/47 (29.8%)	<b>0.03</b>	0.38	0.25	<b>0.02</b>
MCF INTEM < 48mm	6/21 (28.6%)	3/13 (23.1%)	8/47 (17%)	0.52**	-	-	-
MCF EXTEM < 45mm	6/21 (28.6%)	4/13 (30.8%)	4/47 (8.5%)	<b>0.04**</b>	1.00	0.18	0.18
	Neonates born to Early-Onset PE mothers (N=)	Neonates born to Late-Onset PE mothers (N=)	Neonates born to healthy mothers (N=47)	P-Value	Early-Onset PE vs Late Onset PE	Early-Onset PE vs Controls	Late-Onset PE vs Controls
Hyperfibrinolysis	6/21 (28.6%)	4/13 (30.8%)	11/47 (23.4%)	0.83**	-	-	-
MCF FIBTEM < 13mm	14/21 (66.7%)	5/13 (38.5%)	14/47 (29.8%)	<b>0.02</b>	0.63	<b>0.03</b>	1.00
MCF INTEM < 48mm	7/21 (33.3%)	2/13 (15.4%)	8/47 (17%)	0.33**	-	-	-
MCF EXTEM < 45mm	8/21 (38.1%)	2/13 (15.4%)	4/47 (8.5%)	<b>0.01**</b>	1.00	<b>0.02</b>	0.75
	Neonates born to PE mothers (N=34)		P-value	Neonates born to healthy mothers (N=47)		P-Value	
	Hyperfibrinolysis (N=10)	No hyperfibrinolysis (N=24)		Hyperfibrinolysis (N=11)	No hyperfibrinolysis (N=36)		
IL2 <sup>6</sup>	5.7 (5-6.3)	4.9 (4.2-5.5)	0.11*	4.3 (3.3-5.1)	4.5 (2.7-5.4)	0.99*	
IL6 <sup>7</sup>	168.4 (101.7-290)	50.1 (19.3-109.9)	<b>0.01*</b>	233.6 254.1	260.2 385.5	0.87	
IL8 <sup>8</sup>	15.6 (10.6-40.2)	5.8 (4.1-19.6)	0.08*	5.2 (3.5-7.4)	6.5 (4.6-15.1)	0.21*	
TNFa <sup>9</sup>	13.6 (12.1-14.7)	13.2 (10.3-14.9)	0.46*	10.5±2.6	10±2	0.62	
ET1 <sup>10</sup>	1.3 (1-1.5)	1.2 (0.9-1.6)	0.81*	1.2±0.3	1.2±0.4	0.80	
	Neonates born to PE mothers (N=34)		P-value	Neonates born to healthy mothers (N=47)		P-Value	
	MCF FIBTEM < 13mm (N=)	MCF FIBTEM ≥ 13mm (N=)		MCF FIBTEM < 13mm (N=)	MCF FIBTEM ≥ 13mm (N=)		
IL2	5.2 (4.7-5.7)	5 (4.3-5.9)	0.58*	3.9 (2.1-5.7)	4.5 (3.3-5)	0.89*	
IL6	104.8 (28.8-198.2)	61.2 (24.7-132.6)	0.79*	76 (10.4-467.2)	86.1 (14.5-314.6)	0.84*	
IL8	10.9 (4.7-28.5)	5.8 (4.9-23.1)	0.74*	6.2 (4.8-16.5)	6.5 (4.6-11.4)	0.99*	
TNFa	13.4 (12.7-14)	10.8 (10.3-15.6)	0.63*	9.7±2.6	10.3±2	0.59	
ET1	1.5±0.5	1.2±0.3	<b>0.03**</b>	1±0.5	1.2±0.4	0.34	
	Neonates born to PE mothers (N=34)		P-value	Neonates born to healthy mothers (N=47)		P-value	

	MCF INTEM < 48mm (N=9)	MCF INTEM ≥ 48mm (N=25)		MCF INTEM < 48mm (N=8)	MCF INTEM ≥ 48mm (N=39)	
IL2	5.6 (5.5-6.3)	4.8 (4.11-5.23)	<b>0.01*</b>	2.5 (2.3-3.9)	4.5 (3.5-5.6)	0.08 *
IL6	117.9 (100.7-224)	52.4 (19.9-124.4)	0.06*	110.5 (99.9-268.4)	53.2 (6.9-339.7)	0.40 *
IL8	10.9 (8.5-18)	5.8 (4.1-28.8)	0.35*	4.3 (3.3-9.2)	6.5 (4.7-14.7)	0.19 *
TNFα	13.5 (12.4-13.8)	13 (10.3-15.4)	0.59*	8.5 (8-8.7)	10.3 (9.2-12.2)	0.10 *
ET1	1.4 (1-1.7)	1.2 (1-1.4)	0.99*	1 (0.9-1.2)	1.3 (0.9-1.4)	0.72 *
	Neonates born to PE mothers (N=34)			Neonates born to healthy mothers (N=47)		
	MCF EXTEM < 45mm (N=10)	MCF EXTEM ≥ 45mm (N=24)	P- value	MCF EXTEM < 45mm (N=4)	MCF EXTEM ≥ 45mm (N=43)	P-value
IL2	5.6 (5.2-6.1)	4.7 (4.1-5.3)	<b>0.02*</b>	4.5 (3.6-4.7)	4.4 (2.3-5.6)	0.97 *
IL6	112.6 (85.7-211.1)	56 (19.3-134.4)	0.16*	73.2 (61.1-220.2)	99.1 (8.7-318.3)	0.76 *
IL8	10.7 (8.1-16.8)	5.8 (4.5-29.1)	0.66*	10.5 (6.8-30.4)	6.2 (4.6-13.5)	0.77 *
TNFα	13.5 (12-13.8)	13.2 (10.3-15.5)	0.69*	8.7 (8.7-9.6)	10.1 (8.4-11.8)	0.62 *
ET1	1.3 (1-1.7)	1.2 (1-1.5)	1.00*	1.1 (0.8-1.4)	1.2 (0.9-1.4)	0.80 *

<sup>1</sup>PE: Preeclampsia; <sup>2</sup>MCF: Maximum Clot Firmness; <sup>3</sup>FIBTEM: Fibrinogen ROTEM; <sup>4</sup>INTEM: Intrinsic ROTEM; <sup>5</sup>EXTEM: Extrinsic ROTEM; <sup>6</sup>IL2: Interleukin 2; <sup>7</sup>IL6: Interleukin 6; <sup>8</sup>IL8: Interleukin 8; <sup>9</sup>TNFα: Tumor Necrosis Factor α; <sup>10</sup>ET1: Endothelin 1

Regarding numerical variables, p-values were calculated using the two-sample T-Test when the numerical variable followed the normal distribution across the 2 groups.

Regarding categorical variables, p-values were calculated using the Chi-Square test. If p-value ≤ 0.05 across subgroups, a pairwise comparison was conducted, and the p-value was calculated using Bonferroni correction.

\* P-values with one asterisk indicate that the Mann-Whitney U test was conducted since the numerical variable did not follow the normal distribution across the groups.

\*\* P-values with two asterisks (\*\*) indicate that Fisher's exact test was conducted. Fisher's exact test was used when the expected numbers were very small (expected frequencies less than 1, or more than 20% of the expected frequencies less than 5). If p-value ≤ 0.05 across subgroups, a pairwise comparison was conducted, and the p-value was calculated using Bonferroni correction.

\*\*\* P-values with three asterisks (\*\*\*) indicate that Welch's test was conducted. Welch's test was used when the assumption of homogeneity of variances for the 2 groups was not met.

<sup>§</sup>Hyperfibrinolysis: CT (Clotting Time) APTEM (Aprotinin ROTEM) < CT EXTEM (Extrinsic ROTEM) and MCF APTEM > MCF EXTEM and ML (Maximum Lysis) APTEM < 15% and ML EXTEM ≥ 15%